2Q13 Earnings Release
August 15, 2013
Highlights in the Period
• Consolidated gross revenues amounted to R$ 1.0 billion, up 10.6% year-over-year and EBITDA rose by 6.3% to R$ 33.1
million in the same period;
• The Pharmaceutical Distribution division grew sharply by 10.3% year-over-year;
• The Hospital & Specialties division expanded by 12.2% year-over-year and by 17.3% quarter-over-quarter;
• After approval by the regulatory bodies (CADE), Profarma posts the results for the month of June of its retail operation
Tamoio. In this period, it grew by 10.8% year-over-year, with a 4.4% EBITDA margin;
• SAP was introduced as an Integrated System in the Tamoio chain’s financial and accounting divisions in June 2013,
whereas at Arpmed, the development of the SAP System was initiated in April and came to completion in August;
• The consolidated cash cycle was decreased by 2.8 days to 56.3 days. This decrease resulted in a fall of about R$ 24.8
million in working capital.
Gross Revenues Evolution
(R$ million)
919.5
2Q12
774.3
145.2
1,016.9
2Q13
854.0
162.9
1Q13
847.4
138.9
986.3
Pharmaceutical Distribution Hospital & Specialties
Gross Profit Revenues from Services to Suppliers Gross Profit Margin (%)
(R$ million and % Net Revenues)
Gross Profit and Revenues from Services to Suppliers
2Q12
42.0
52.8
1Q13
37.3
58.5
2Q13
31.3
82.5
12.9%
12.4%
11.2%
2Q132Q12
64.5
1Q13
74.0
8.6%
8.4%
9.0%
(R$ million and % Net Revenues)
Operating Expenses - SGA
79.0
2Q12
31.2
1Q13
18.8
2Q13
33.12.2%
3.8%
4.1%
(R$ million and % Net Revenues)
Ebitda and Ebitda Margin
2Q13
11.5
2Q12
10.5
1Q13
10.9
(R$ million and % Net Revenues)
Net Financial Expenses
1.4% 1.3% 1.3%
(R$ million and % Net Revenues)
Net Profit
1.4%
1.6%
0.8%
2Q13
6.9
2Q12
12.4
1Q13
12.6
2Q12
18.2
30.5
(12.3)
52.7
34.2
(93.5)
(5.7)
(2.7)
(4.2)
11.3
(R$ Million)
Cash Flow Generated / (Used) in Operating Activities
Internal Cash Generation
Operating Assets Variation
Trade Accounts Receivable
Inventories
Suppliers
Other Items
Cash Flow (Used) in Investing Activities
Cash Flow Generated / (Used) by Financing Activities
Net Increase / (Decrease) in Cash
Summary of Cash Flow
2Q13
(31.6)
23.6
(55.2)
28.0
(14.4)
(88.2)
19.4
(78.8)
72.4
(38.0)
Chg. %
-
-22.7%
-349.8%
-46.9%
-
5.7%
-
-
-
-
1Q13
(61.9)
14.0
(75.8)
(102.6)
5.0
33.7
(11.9)
(1.1)
132.3
69.4
Chg. %
48.9%
68.5%
27.3%
-
-
-
-
-
-45.3%
-
* Average
(1) Average of Gross Revenues in the Quarter
(2) Average of COGS in the Quarter
(3) Average of COGS in the Quarter
Cash Cycle - Days *
Accounts Receivable (1)
Inventories (2)
Accounts Payable (3)
55.1
49.1
47.9
2Q13
56.3
59.5
47.4
55.8
1Q13
51.1
47.4
48.9
37.1
2Q12
59.1
(R$ milllion)
Indebtedness: Net Debt and Net Debt / Ebitda
2Q13
359.4
2Q12
202.0
1Q13
236.5
2.2x 2.6x
3.3x
2Q13
1.7
2Q12
2.9
1Q13
1.0
(R$ million and % Net Revenues)
Capex
0.1%
0.4%
0.2%
Nível de Serviço
(Unidades atendidas / Unidades pedidas)
Logistics E.P.M.
(Errors per Million)
2Q12
87.9%
2Q13
88.9%
1Q13
87.4%
2Q12
107.0
118.0
2Q131Q13
115.0
Gross Revenues
R$ million
28.7
Op. Exp.
Total
Gross
Margin
Ebitda
Margin
Net
Margin
24.0%
28.6%
Financial DataTamoio – jun/13
(R$ million e % Gross Revenues)
57
7
8.7%
25.35
503.1
21.2
# of stores
Store Openings
1
SSS Mature Stores (more than 36 months)
Average Ticket (in reais)
Average Store's Sales
Revenues per Employee
1- Same Store Sales
8.1%1SSS
Operational Data Tamoio – jun/13
(R$ thousands)
4.4% 3.7%
Turnover - PFRM3 PFRM3 IBOV Index IGCX Index
Stock Performance
100
8.3
-8.7
-22.1
100
Analyst Coverage
Company Analyst Phone number Email address
Credit Suisse Marcel Moraes (55 11) 3841-6302 marcel.moraes@credit-suisse.com
BTG Pactual João Carlos dos Santos (55 11) 3383-2384 joaocarlos.santos@btgpactual.com
Juliana Rozenbaum (55 11) 3073-3040 juliana.rozenbaum@itausecurities.comItaú BBA
Javier Martinez de Olcoz (55 11) 3048-6088 javier.martinez.olcoz@morganstanley.comMorgan Stanley
Andre Parize (55 11) 5171-5870 andre.parize@votorantimcorretora.com.brVotorantim
Merrill Lynch Mauricio Fernandes (55 11) 2188-4236 mauricio.fernandes@baml.com
Banco Fator Pedro Ivo Barreto Zabeu (55 11) 3049-9478 pzabeu@bancofator.com.br
Guilherme Assis (55 11) 3206-8285 guilherme.assis@brasilplural.com.brBrasil Plural
Contatos RI
Max Fischer | Diretor Financeiro e de RI
Beatriz Diez | Gerente de RI
Telefone.: 55 (21) 4009-0276 | E-mail: ri@profarma.com.br | www.profarma.com.br/ri
IR contacts
Max Fischer | Chief Financial and IR Officer
Beatriz Diez | IR Manager
Phone number: 55 (21) 4009-0276 | E-mail: ri@profarma.com.br | www.profarma.com.br/ir

Profarma 2Q13

  • 2.
  • 3.
    Highlights in thePeriod • Consolidated gross revenues amounted to R$ 1.0 billion, up 10.6% year-over-year and EBITDA rose by 6.3% to R$ 33.1 million in the same period; • The Pharmaceutical Distribution division grew sharply by 10.3% year-over-year; • The Hospital & Specialties division expanded by 12.2% year-over-year and by 17.3% quarter-over-quarter; • After approval by the regulatory bodies (CADE), Profarma posts the results for the month of June of its retail operation Tamoio. In this period, it grew by 10.8% year-over-year, with a 4.4% EBITDA margin; • SAP was introduced as an Integrated System in the Tamoio chain’s financial and accounting divisions in June 2013, whereas at Arpmed, the development of the SAP System was initiated in April and came to completion in August; • The consolidated cash cycle was decreased by 2.8 days to 56.3 days. This decrease resulted in a fall of about R$ 24.8 million in working capital.
  • 4.
    Gross Revenues Evolution (R$million) 919.5 2Q12 774.3 145.2 1,016.9 2Q13 854.0 162.9 1Q13 847.4 138.9 986.3 Pharmaceutical Distribution Hospital & Specialties
  • 5.
    Gross Profit Revenuesfrom Services to Suppliers Gross Profit Margin (%) (R$ million and % Net Revenues) Gross Profit and Revenues from Services to Suppliers 2Q12 42.0 52.8 1Q13 37.3 58.5 2Q13 31.3 82.5 12.9% 12.4% 11.2%
  • 6.
    2Q132Q12 64.5 1Q13 74.0 8.6% 8.4% 9.0% (R$ million and% Net Revenues) Operating Expenses - SGA 79.0
  • 7.
    2Q12 31.2 1Q13 18.8 2Q13 33.12.2% 3.8% 4.1% (R$ million and% Net Revenues) Ebitda and Ebitda Margin
  • 8.
    2Q13 11.5 2Q12 10.5 1Q13 10.9 (R$ million and% Net Revenues) Net Financial Expenses 1.4% 1.3% 1.3%
  • 9.
    (R$ million and% Net Revenues) Net Profit 1.4% 1.6% 0.8% 2Q13 6.9 2Q12 12.4 1Q13 12.6
  • 10.
    2Q12 18.2 30.5 (12.3) 52.7 34.2 (93.5) (5.7) (2.7) (4.2) 11.3 (R$ Million) Cash FlowGenerated / (Used) in Operating Activities Internal Cash Generation Operating Assets Variation Trade Accounts Receivable Inventories Suppliers Other Items Cash Flow (Used) in Investing Activities Cash Flow Generated / (Used) by Financing Activities Net Increase / (Decrease) in Cash Summary of Cash Flow 2Q13 (31.6) 23.6 (55.2) 28.0 (14.4) (88.2) 19.4 (78.8) 72.4 (38.0) Chg. % - -22.7% -349.8% -46.9% - 5.7% - - - - 1Q13 (61.9) 14.0 (75.8) (102.6) 5.0 33.7 (11.9) (1.1) 132.3 69.4 Chg. % 48.9% 68.5% 27.3% - - - - - -45.3% -
  • 11.
    * Average (1) Averageof Gross Revenues in the Quarter (2) Average of COGS in the Quarter (3) Average of COGS in the Quarter Cash Cycle - Days * Accounts Receivable (1) Inventories (2) Accounts Payable (3) 55.1 49.1 47.9 2Q13 56.3 59.5 47.4 55.8 1Q13 51.1 47.4 48.9 37.1 2Q12 59.1
  • 12.
    (R$ milllion) Indebtedness: NetDebt and Net Debt / Ebitda 2Q13 359.4 2Q12 202.0 1Q13 236.5 2.2x 2.6x 3.3x
  • 13.
    2Q13 1.7 2Q12 2.9 1Q13 1.0 (R$ million and% Net Revenues) Capex 0.1% 0.4% 0.2%
  • 14.
    Nível de Serviço (Unidadesatendidas / Unidades pedidas) Logistics E.P.M. (Errors per Million) 2Q12 87.9% 2Q13 88.9% 1Q13 87.4% 2Q12 107.0 118.0 2Q131Q13 115.0
  • 15.
    Gross Revenues R$ million 28.7 Op.Exp. Total Gross Margin Ebitda Margin Net Margin 24.0% 28.6% Financial DataTamoio – jun/13 (R$ million e % Gross Revenues) 57 7 8.7% 25.35 503.1 21.2 # of stores Store Openings 1 SSS Mature Stores (more than 36 months) Average Ticket (in reais) Average Store's Sales Revenues per Employee 1- Same Store Sales 8.1%1SSS Operational Data Tamoio – jun/13 (R$ thousands) 4.4% 3.7%
  • 16.
    Turnover - PFRM3PFRM3 IBOV Index IGCX Index Stock Performance 100 8.3 -8.7 -22.1 100
  • 17.
    Analyst Coverage Company AnalystPhone number Email address Credit Suisse Marcel Moraes (55 11) 3841-6302 marcel.moraes@credit-suisse.com BTG Pactual João Carlos dos Santos (55 11) 3383-2384 joaocarlos.santos@btgpactual.com Juliana Rozenbaum (55 11) 3073-3040 juliana.rozenbaum@itausecurities.comItaú BBA Javier Martinez de Olcoz (55 11) 3048-6088 javier.martinez.olcoz@morganstanley.comMorgan Stanley Andre Parize (55 11) 5171-5870 andre.parize@votorantimcorretora.com.brVotorantim Merrill Lynch Mauricio Fernandes (55 11) 2188-4236 mauricio.fernandes@baml.com Banco Fator Pedro Ivo Barreto Zabeu (55 11) 3049-9478 pzabeu@bancofator.com.br Guilherme Assis (55 11) 3206-8285 guilherme.assis@brasilplural.com.brBrasil Plural
  • 18.
    Contatos RI Max Fischer| Diretor Financeiro e de RI Beatriz Diez | Gerente de RI Telefone.: 55 (21) 4009-0276 | E-mail: ri@profarma.com.br | www.profarma.com.br/ri IR contacts Max Fischer | Chief Financial and IR Officer Beatriz Diez | IR Manager Phone number: 55 (21) 4009-0276 | E-mail: ri@profarma.com.br | www.profarma.com.br/ir